Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Amelioration of LPS-Induced Inflammation Response in Microglia by AMPK Activation.
NMR and pattern recognition methods in metabolomics: From data acquisition to biomarker discovery: A review.
Accurately diagnosing and comprehensively managing MS.
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.
FRACTALKINE GENE RECEPTOR POLYMORPHISM IN PATIENTS WITH MULTIPLE SCLEROSIS.
Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats.
Early CNS neurodegeneration in radiologically isolated syndrome.
Longitudinal follow-up of vision in a neuromyelitis optica cohort.
Self-Efficacy as a Longitudinal Predictor of Perceived Cognitive Impairment in Individuals with Multiple Sclerosis.
Recruitment of participants to a multiple sclerosis trial: The CombiRx experience.
Response to Letter to the Editor 'Simvastatin improves final visual outcome in acute optic neuritis, a randomized study'
A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
[Multiple sclerosis in Argentina. Systematic review and meta-analysis].
The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis.
Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
Gender and Uveitis in Patients with Multiple Sclerosis.
RANDOM FOREST FLAIR RECONSTRUCTION FROM T 1, T 2, AND PD -WEIGHTED MRI.
Central Neuropathic Pain Syndromes.
Therapy optimization: a new model for managing high-cost biologics.
Neuropsychological rehabilitation does not improve cognitive performance but reduces perceived cognitive deficits in patients with multiple sclerosis: a randomised, controlled, multi-centre trial.
Multiple sclerosis decreases explicit counterfactual processing and risk taking in decision making.
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies.
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
Self-rating makes the difference: Identifying palliative care needs of patients feeling severely affected by multiple sclerosis.
Long-term outcome of paediatric-onset multiple sclerosis: a population-based study.

Pages